-

02:02:33 PM

AORT Stock News

AORT - Artivion Inc

09/23/22 7:00 AM

NYSE : AORT

clinical trial

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical

RHEA-AI

neutral

09/14/22 8:10 AM

NYSE : AORT

conferences

Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 30 th Annual Leveraged Finance Conference on Wednesday, September 21, 2022. The

RHEA-AI

neutral

09/06/22 4:10 PM

NYSE : AORT

conferences

Artivion to Participate in Upcoming Investor Conferences

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.Artivion's management team will present at the upcoming Morgan Stanley 20 th

RHEA-AI

neutral

08/24/22 4:10 PM

NYSE : AORT

conferences

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022.

RHEA-AI

neutral

08/04/22 4:05 PM

NYSE : AORT

earnings

Artivion Reports Second Quarter 2022 Financial Results

Second Quarter and Recent Business Highlights:Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first

RHEA-AI

positive

08/03/22 8:25 AM

NYSE : AORT

conferences

Artivion to Participate in Upcoming Investor Conferences

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.Artivion's management team will present at the upcoming Canaccord Genuity 42

RHEA-AI

neutral

07/27/22 8:25 AM

NYSE : AORT

clinical trial

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic

RHEA-AI

neutral

07/21/22 8:25 AM

NYSE : AORT

earnings

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022 financial results will be released on Thursday, August 4, 2022 after the market closes. On that day, the Company

RHEA-AI

neutral

05/16/22 8:25 AM

NYSE : AORT

conferences

Artivion to Participate in the UBS 2022 Global Healthcare Conference

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace. The

RHEA-AI

neutral

05/05/22 4:05 PM

NYSE : AORT

earnings

Artivion Reports First Quarter 2022 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular

RHEA-AI

positive